This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted at raymond.miller@dlapiper.com. When it comes to protecting therapeutic assets, I…
Posts published in “Guest Content”
This paper was originally published by Andreas H. Göller, Lara Kuhnke, Floriane Montanari, Anne Bonin, Sebastian Schneckener, Antoniuster Laak, Jörg Wichard, Mario Lobell, and Alexander Hillisch in Drug Discovery Today…
Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review
0
This paper was originally published by Md. Imtiaz Hasan et al in Journal of Biosciences and Medicines under a Creative Commons Attribution 4.0 International License Abstract Development of generic drug product…
This article was originally published by Sajna T. in Management Insight, 16(1):38-40 under a creative commons license. Abstract Business enterprises are an important organ of society. The impact of a…
This is a guest post by Shamil Gizatullin, Gowling WLG (International) Inc. shamil.gizatullin@gowlingwlg.com Although it has become harder to obtain patent-term extensions for drugs, pesticides or agricultural chemicals, a careful…
By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity planning and why it is important? Emergencies may be infrequent…
This is a guest post from Pepper Hamilton Partners John P. Isacson and N. Nicole Stakleff. John can be contacted at isacsonj@pepperlaw.com and Nicole can be contacted at stakleffn@pepperlaw.com. The Federal Circuit recently…
Former Congressman Henry Waxman was recently interviewed for the Clause 8 podcast about how he worked together with Sen. Orrin Hatch to pass the Hatch-Waxman Act and its aftermath. Congressman…
This paper was originally published by Bhaven N. Sampat and Kenneth C. Shadlen in PLoS ONE 13(4): e0194714 under a Creative Commons license. Abstract India, like many developing countries, only recently…
Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
0
This paper was originally published by Rishi J Desai, Ameet Sarpatwari, Sara Dejene, Nazleen F Khan, Joyce Lii, James R Rogers, Sarah K Dutcher, Saeid Raofi, Justin Bohn, John Connolly, Michael A Fischer, Aaron S Kesselheim, and Joshua J Gagne in BMJ 2018; 361 under…
